ArfGAP with GTPase domain, ankyrin repeat and PH domain 6Genealiases: AGAP-6 · CTGLF3
Q-omics provides the consensus-scored AGAP6 profile across patient tissues and cancer cell-line models. AGAP6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGAP6 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, AGAP6 RNA expression shows 19,972 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where AGAP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGAP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGAP6 survival associations across molecular data types. AGAP6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGAP6 RNA expression–survival associations across cancer types. High AGAP6 expression shows unfavorable associations in KIRC, ACC, COAD, KICH and LIHC, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGAP6 RNA expression.
This table summarizes AGAP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for AGAP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGAP6 shows lower tumor expression in BRCA and higher tumor expression in COAD, LIHC, KIRC, UCEC and HNSC. The COAD box plot shows higher AGAP6 RNA expression in tumor versus normal tissue (log2 FC = +0.878, t-test p < 0.001).
This table shows molecular features associated with AGAP6 in patient tissues and cancer cell lines. In patient samples, AGAP6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGAP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
